Introduction
============

Alzheimer\'s disease (AD) is the most common underlying cause of dementia globally, and the leading cause of years lost to disability in high-income countries as well as the second greatest cause of this worldwide according to the World Health Organization. A definite diagnosis of AD can only be established by postmortem studies that demonstrate the presence of extracellular amyloid plaques and intracellular tau neurofibrillary tangles \[[@B1]\]. The measurement of the neuropathologic hallmarks of AD, namely tau and amyloid beta (Aβ), in cerebrospinal fluid (CSF) has been shown to be a reliable diagnostic biomarker for AD \[[@B2]\], but it would be attractive to have less invasive AD biomarkers, such as those that can be measured in plasma. Positron emission tomography (PET) using florbetapir-F18 (AV-45) or Pittsburgh Compound-B-C11 (PiB) as radiotracers reflects fibrillar brain amyloid deposits and is deemed a reliable method to measure brain amyloid plaque burden \[[@B3],[@B4]\], but cost and availability of PET biomarker measures are drawbacks associated with this diagnostic strategy. Therefore, the measurement of Aβ in plasma would be the least invasive and most cost-effective biomarker assay. In addition, blood samples could readily be obtained in nonspecialized facilities and sent to specialized laboratories to conduct the measurements. However, published results on the correlation of plasma Aβ with the presence of AD are contradictory and plasma Aβ measurements are subject to more sources of variability than CSF Aβ measurements \[[@B5]\]. Below we will summarize the demographic, biological and technical aspects related to Aβ plasma measures, the results of cross-sectional and longitudinal studies in populations with sporadic AD and AD due to autosomal dominant genetic inheritance, and application of these measurements in clinical trials.

Aβ distribution in blood, CSF and brain
=======================================

Aβ production and correlation between plasma, CSF and parenchymal Aβ measurements
---------------------------------------------------------------------------------

Aβ is a byproduct of Aβ precursor protein (APP) metabolism that is generated by nearly all cells, and amyloid plaques are the result of the deposition of mainly Aβ~1-40~and Aβ~1-42~in the brain, although other species of Aβ are also present \[[@B6]\]. The mechanism leading to Aβ deposition differs in subjects for whom this occurs on a genetic basis, leading to familial AD (FAD), versus those who develop sporadic AD. In autosomal dominantly inherited forms of AD, the main mechanism is an increased production of Aβ species \[[@B7]\], while the consensus is that there is a decreased Aβ clearance in sporadic forms of AD, which is modulated by the apolipoprotein E (APOE) genotype \[[@B8],[@B9]\].

The blood-brain barrier and the blood-CSF barrier regulate the passage of solutes between blood and the central nervous system (CNS), including Aβ. Although there are a number of receptors that are implicated in the influx (for example, receptor of advanced glycation end products) and efflux (for example, low-density lipoprotein receptor, low-density lipoprotein receptor-related protein 1 and 2, P-glycoprotein, low-density and very low-density lipoprotein receptor) of Aβ through the blood-brain barrier, most of the studies that compared plasma Aβ levels with their CSF counterparts \[[@B10]-[@B13]\] or the binding of PET Aβ radiotracers \[[@B10],[@B14]\] have found no or low correlations between Aβ plasma measurements and CSF Aβ and PET amyloid plaque measurements. On the other hand, CSF and PET values show a high inverse correlation \[[@B10],[@B15],[@B16]\], although CSF ELISA/Luminex assays measure soluble Aβ and PIB/AV-45 PET measure insoluble fibrillar Aβ deposition. However, one study has described a stronger correlation between plasma Aβ and PET PiB measurements \[[@B17]\].

Origin, distribution and clearance of Aβ in plasma
--------------------------------------------------

There are several factors that can explain the low correlation between plasma and CSF Aβ/PET amyloid plaque measurements. First, Aβ species in the CSF and the CNS interstitial fluid originate in the CNS. CNS Aβ is then thought to diffuse from interstitial fluid into the CSF, while passage of Aβ through the blood-brain barrier is limited. In addition, Aβ in plasma and blood does not originate only in the brain since it also is the product of APP metabolism in skeletal muscle, pancreas, kidney, liver, vascular walls, lung, intestine, skin and several glands and APP can be found in almost all peripheral cells \[[@B18]-[@B20]\]. In addition, most of the Aβ~1-40~and Aβ~1-42~in plasma are bound to several proteins (that is, apolipoprotein A-I, A-IV, E and J, α2-macroglobulin, complement factors, immunoglobulins, transthyretin, apoferritin and serum amyloid P component) and erythrocytes\[[@B19],[@B21]\]. Finally, platelets are another important source of Aβ~1-40~and Aβ~1-42~in plasma \[[@B19]\] and activated platelets release APP and Aβ \[[@B22]\]. Therefore, it is not surprising that Aβ plasma values may only partially reflect altered APP metabolism or Aβ in the CNS since there is no evidence that AD is a systemic Aβ amyloidosis. While correlations between undiluted, diluted and cell bound plasma samples have been reported by some investigators to be high, the diagnostic utility of measuring Aβ at different dilutions or in different fractions remains uncertain \[[@B23]\]. Finally, regarding the elimination of plasma Aβ, animal models have implicated the liver as the major organ responsible for the clearance of Aβ from plasma \[[@B24]\], followed by renal clearance \[[@B25]\].

Demographic, clinical, genetic and technical issues affecting Aβ levels and measurements
========================================================================================

Demographic, genetic diagnostic and assay related factors affecting Aβ plasma levels
------------------------------------------------------------------------------------

Most studies have described a strong association between older age and higher levels of plasma Aβ \[[@B10],[@B26]-[@B31]\]. This association has not been established in Down syndrome (DS) subjects, and there are conflicting results, with some studies finding an association \[[@B32],[@B33]\] and others not \[[@B34],[@B35]\]. Two studies have evaluated the heritability of Aβ plasma levels. The paper by Ertekin-Taner *et al.*found a higher heritability (54% for Aβ~1-40~and 73% for Aβ~1-42~) \[[@B36]\] than the one by Ibrahim-Verbaas *et al.*(23% for Aβ~1-40~and 30% for Aβ~1-42~) \[[@B37]\]. None of the studies found that APOE genotype explained a significant amount of the heritability, but the study by Ibrahim-Verbaas *et al.*found an association between SNPs located at the presenilin 2 gene (*PSEN2*) and Aβ~1-40~levels. However, some studies have reported an association of lower Aβ~1-42~in the presence of APOE ε4 alleles \[[@B10],[@B28],[@B38]\] and at least one study has described a lower Aβ~1-42~/Aβ~1-40~ratio in non-APOE ε4 subjects in the highest tertile of physical activity \[[@B39]\]. A third study found increased Aβ in young, non-demented first-degree relatives of late onset AD compared to unrelated controls \[[@B31]\]. Other factors associated with Aβ plasma levels are creatinine levels \[[@B10],[@B28],[@B38],[@B40]\], high density lipoproteins \[[@B27]\], body mass index \[[@B27]\], race \[[@B38]\] and sex \[[@B38],[@B41]\]. One study included age, platelet count, total protein concentration and creatinine levels in a multivariate analysis and found that these variables accounted for 12.9% of plasma levels, underscoring the importance of using multivariable models that adjust for possible confounders \[[@B10]\]. Like CSF levels, plasma levels show a circadian fluctuation that decreases with aging \[[@B11]\]. Therefore, standardization of sampling time is important.

Technical aspects regarding sample storage and Aβ plasma measurements
---------------------------------------------------------------------

Aβ~1-40~and Aβ~1-42~are stable at 2 to 8°C for 6 h but when Aβ is kept at room temperature for 24 h levels drop considerably, exceeding a 20% loss in most of the pools \[[@B42]-[@B45]\], although ratios of different Aβ species can be more stable \[[@B43]\]. Storage at -20°C is not suitable for long-term storage and Aβ levels are not stable through freeze-thaw cycles following storage at -20°C, whereas storage at-70°C shows no reductions in Aβ levels for up to three cycles and Aβ levels are stable for at least 12 months when stored at this temperature \[[@B42],[@B45]\]. One study has reported that some Aβ peptides increase their concentration once frozen \[[@B46]\]. Repeated samples taken during fasting and in the post-prandial state and repeated samples taken from cognitively normal (CN) subjects within three weeks show coefficients of variation (CV) that are within the range of the variability of the assay in both cases, indicating that these pre-analytical factors do not have an important effect on Aβ measurements \[[@B13]\]. Although not formally tested in plasma, storage in polypropylene tubes currently is the best way to minimize adherence of Aβ to the wall of storage vials compared to polystyrene for CSF samples \[[@B47]\], and is current practice for plasma samples. Different types of polypropylene are used in the manufacture of biofluid storage vials, but the effects of these differences on Aβ levels following short- and long-term storage are not well documented. Finally, collection parameters like collected blood volume and time to freeze have been associated with levels of plasma Aβ \[[@B48]\] and Aβ levels in serum are also less stable than plasma Aβ levels \[[@B43]\].

Association of Aβ with AD and cerebrovascular disease
=====================================================

Cross-sectional and longitudinal results in DS individuals and subjects harboring autosomal dominant FAD mutations
------------------------------------------------------------------------------------------------------------------

The initial study by Scheuner *et al.*described increased plasma levels of Aβ~1-42~in subjects from FAD kindreds with pathogenic mutations in the *APP*, *PSEN1*and *PSEN2*genes when compared to non-mutation bearing controls \[[@B49]\] and Kosaka *et al.*found increased plasma levels of Aβ~1-42~when comparing AD patients carrying the βAPP717 mutation to sporadic AD patients \[[@B50]\]. Recently, a cross-sectional cohort of asymptomatic carriers of the PSEN1 E280A mutation had higher Aβ~1-42~and Aβ~1-42~/Aβ~1-40~than matched CN controls without the mutation \[[@B51]\].

DS subjects show higher plasma Aβ~1-42~and Aβ~1-40~levels than CN subjects without trisomy 21 \[[@B34],[@B52]\]. Two studies found no differences comparing DS with and without dementia, although an association between Aβ levels and neuropsychological scores in multivariable adjusted models was found \[[@B34],[@B35]\]. In one of these studies demented DS (dDS) subjects with longer dementia duration showed higher Aβ~1-42~, lower Aβ~1-40~and a higher Aβ~1-42~/Aβ~1-40~ratio than those with shorter dementia duration \[[@B35]\]. Two other studies comparing dDS to cognitively normal DS (cnDS) found a higher Aβ~1-42~/Aβ~1-40~ratio in dDS \[[@B53]\] and increased Aβ~1-40~levels in dDS subjects compared to cnDS that remained stable during a follow-up of several years \[[@B54]\]. Consecutive studies by Schupf *et al.*\[[@B32],[@B52]\] have described increased Aβ~1-42~in dDS when compared to cnDS. These and other studies of plasma Aβ levels in subjects with trisomy 21 and pathogenic FAD mutations are summarized in Table [1](#T1){ref-type="table"}.

###### 

Cross-sectional studies in populations including Down syndrome and familial Alzheimer\'s disease due to trisomy 21 or autosomal dominant mutations, respectively

                                                                                Values in DS patients compared to controls        Values in dDS compared to cnDS                 
  ---------------------------------- -------------- ------ ---------- --------- -------------------------------------------- ---- -------------------------------- -- ----- ---- ----
  Schupf *et al.*2001 \[[@B52]\]     97 cnDS        51.9   ELISA      \-        ↑                                            ↑    \-                                  =     ↑    \-
                                     11 dDS         56     6E10                                                                                                                  
                                                           R182                                                                                                                  
                                                           R165                                                                                                                  
  Schupf *et al.*2007 \[[@B32]\]                           ELISA      \-        \-                                           \-   \-                                  =     ↑    \-
                                                           6E10                                                                                                                  
                                                           R182                                                                                                                  
                                                           R165                                                                                                                  
  Matsuoka *et al.*2009 \[[@B53]\]   148 cnDS       54.2   ELISA      \<11.0%   \-                                           \-   \-                                  =     =    ↑
                                     52 dDS         56.0   82E1                                                                                                                  
                                                           1A10                                                                                                                  
                                                           1C3                                                                                                                   
  Prasher *et al.*2010 \[[@B35]\]    83 cnDS        49.0   ELISA      \-        \-                                           \-   \- =                                = =        a
                                     52dDS          56.8   6E10                                                                                                                  
                                                           R182                                                                                                                  
                                                           R165                                                                                                                  
  Head *et al.*2011 \[[@B34]\]       11 yCN         46.5   ELISA      \-        ↑                                            ↑    =                                   \-    \-   \-
                                     12 aCN         74.2   Wako                                                                                                                  
                                     17 AD          75.3                                                                                                                         
                                     43 cnDS        45                                                                                                                           
                                     52 dDS         53.3                                                                                                                         
  Coppus *et al.*2012 \[[@B54]\]     62 dDS         54     xMAP       \-        \-                                           \-   \-                                  ↑     =    =
                                     264 cnDS       50.6   INNO-BIA                                                                                                              
  Reiman *et al.*2012 \[[@B51]\]     10 PSEN1+ CN   23     xMAP       \-        \-                                           \-   \-                                  \-    \-   \-
                                     10 PSEN1- CN   24     INNO-BIA                                                                                                              

^a^dDS who had a dementia history of 4 or more years had increased Aβ~1-42~/Aβ~1-40~compared with dDS with a more recent diagnosis. aCN, aged cognitively normal controls; AD, Alzheimer\'s disease; CN, cognitively normal; cnDS, cognitively normal Down syndrome; CV, coefficient of variation; dDS, demented Down syndrome; DS, Down syndrome; yCN, young cognitively normal controls.

There are limited data from prospective studies of plasma Aβ levels in subjects with DS (Table [2](#T2){ref-type="table"}), but one study described an increased risk of dementia in subjects who at baseline had increased levels of Aβ~1-42~or Aβ~1-40~\[[@B54]\]. However, in studies conducted by another group, only baseline levels of Aβ~1-42~were associated with an increased risk of dementia and death \[[@B32]\]. Finally, in a third study, Schupf *et al.*\[[@B33]\] compared the measurements of the last and baseline visits, finding an increased risk of dementia with an increase in Aβ~1-40~, a decrease in Aβ~1-42~or a decrease in Aβ~1-42~/Aβ~1-40~ratio with repeated sampling during follow-up.

###### 

Longitudinal studies in populations including Down syndrome

  Study                            Subjects   Mean age (years)   Follow-up duration   Platform and antibodies   CV   Analyte associated with conversion risk   Magnitude
  -------------------------------- ---------- ------------------ -------------------- ------------------------- ---- ----------------------------------------- -----------
  Schupf *et al.*2007 \[[@B32]\]   44 DSp     \-                 5 years^a^           ELISA                     \-   baseline Aβ~1-42~                         HR = 2.6
                                   130 cnDS                                           6E10                                                                     
                                                                                      R182                                                                     
                                                                                      R165                                                                     
                                                                                                                                                               
  Schupf *et al.*2010 \[[@B33]\]   61 DSp     53.7               \-                   ELISA                     \-   Decrease of Aβ~1-40~                      HR = 0.4
                                   164 cnDS   50.3                                    6E10                           Stable Aβ~1-42~                           HR = 2.6
                                                                                      R182                           Decrease Aβ~1-42~                         HR = 4.9
                                                                                      R165                           Stable Aβ~1-42~/Aβ~1-40~                  HR = 3.9
                                                                                                                     Decrease Aβ~1-42~/Aβ~1-40~                HR = 4.9
                                                                                                                                                               
  Coppus *et al.*2012 \[[@B54]\]   79 DSp     53.3               \-                   xMAP                           ↑ baseline Aβ~1-40~                       HR = 2.05
                                   264 cnDS   50.6                                    INNO-BIA                       ↑ baseline Aβ~1-42~                       HR = 2.56

^a^Estimated by author of review. cnDS, cognitively normal Down syndrome; CV, coefficient of variation; DSp, Down syndrome subjects who progress to a dementia diagnosis; HR, hazard ratio.

Cross-sectional results in sporadic AD cases
--------------------------------------------

Results differ between studies including CN and sporadic AD subjects (Table [3](#T3){ref-type="table"}). Different associations have been reported, with increased levels of Aβ~1-42~in AD patients \[[@B27]\], decreased levels of Aβ~1-42~in AD \[[@B14]\] and increased Aβ~1-40~in AD \[[@B55]\]. Regarding the gender effect, one study found higher Aβ~1-42~levels in women with mild cognitive impairment (MCI) compared to CN women and CN and MCI male subjects \[[@B41]\].

###### 

Cross-sectional studies in populations including sporadic Alzheimer\'s disease patients

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                                                        Values in AD patients             
  ------------------------------------------------------------------ ------------------- -------------------------- --------------------------- ------- ----------------------- ---- ---- -------------------------------------------------------------
  Mehta *et al.*2000 \[[@B55]\]                                      61 CN\              67\                        ELISA 6E10\                 \<18%   ↑                       =    \-   
                                                                     78 AD               74                         R162\                                                                 
                                                                                                                    R164                                                                  

  Mayeux *et al.*2003 \[[@B27]\]                                     79 AD\              83.2 75.5                  ELISA 6E10\                 \-      =                       ↑    NA   
                                                                     365 CN                                         R182\                                                                 
                                                                                                                    R165                                                                  

  Fukumoto *et al.*2003 \[[@B26]\]                                   92 CN\              69\                        ELISA Takeda                \<10%   =                       =    =    
                                                                     96 PD\              66.0 72.6\                                                                                       
                                                                     37 MCI\             76                                                                                               
                                                                     146 AD                                                                                                               

  Assini *et al.*2004 \[[@B41]\]                                     72 CN\              73\                        ELISA IBL                   \-      \-                      \-   \-   Increased Aβ~1-42~in MCI women
                                                                     88 MCI              75                                                                                               

  Lewczuk *et al.*2010 \[[@B56]\]                                    137 MCIp\           67.4 63.3 70.8 66.6        xMAP INNO-BIA               \<10%   \-                      \-   \-   MCI and AD with AD-like CSF ↓ Aβ~1-42~& ↓ Aβ~1-42/~Aβ~1-40~
                                                                     62 MCI-OD 127 AD\                                                                                                    
                                                                     25 OD                                                                                                                

  Lui *et al.*2010 \[[@B14]\]                                        724 CN\             70.0 75.9 78.6             ELISA Mehta xMAP INNO-BIA   \-      =                       ↓    =    
                                                                     122 MCI\                                                                                                             
                                                                     186 AD                                                                                                               

  Le Bastard *et al.*2010 \[[@B12]\]                                 47 CN\              69\                        xMAP INNO-BIA               \<10%   =                       =    =    ↓ Aβ~1-42/~Aβ~N-42~
                                                                     50 non-AD\          74\                                                                                              
                                                                     47 AD               82                                                                                               

  Toledo *et al.*2011 \[[@B10]\], Figurski *et al.*2012 \[[@B48]\]   187 CNs\            75.8 78.4 74.7 74.6 75.3   xMAP INNO-BIA               \<10%   =                       =    =    Interaction between age and diagnosis defined by CSF
                                                                     10 CNp\                                                                                                              
                                                                     162 MCIs\                                                                                                            
                                                                     145 MCIp\                                                                                                            
                                                                     162 AD                                                                                                               
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AD, Alzheimer\'s disease; CN, cognitively normal; CNp, cognitively normal progression; CNs, cognitive normal stable; CV, coefficient of variation; MCI, mild cognitive impairment; MCI-OD, mild cognitive impairment, progression to non-AD dementia; MCIp, mild cognitive impairment progressor (to AD); MCIs, mild cognitive impairment stable; NA, not available; OD, other dementia; PD, Parkinson\'s disease.

Some studies classified subjects not only based on clinical diagnosis but also on AD-like CSF profiles for tau and Aβ profiles \[[@B10],[@B13],[@B56]\]. In a study that included CN and MCI subjects, the group of CN and MCI subjects with AD-like CSF tau and Aβ profiles showed lower plasma Aβ~1-42~/Aβ~1-40~than CN and MCI subjects with normal CSF tau and Aβ levels \[[@B13]\]. Another study found decreased Aβ~1-42~and Aβ~1-42~/Aβ~1-40~in MCI and AD subjects with an AD-like CSF tau and Aβ signature when compared to MCI and AD subjects with normal CSF tau and Aβ levels \[[@B56]\]. A more complex association was found for plasma Aβ~1-40~and Aβ~1-42~levels in the AD Neuroimaging Initiative (ADNI) cohort, showing an interaction between age and diagnostic groups defined by an AD-like CSF tau and Aβ profile \[[@B10]\]. Based on these results, only younger MCI and AD subjects with an AD-like CSF signature showed lower Aβ~1-40~and Aβ~1-42~values than older MCI and AD subjects with an AD-like CSF signature or subjects with a normal CSF signature. These findings indicate that the presence of AD-like CSF in younger cognitively impaired subjects was what defined the group with lower plasma Aβ. There were not enough CN subjects with AD-like CSF to test the association in this group of subjects who are in the pre-symptomatic stage of AD. Although most of these studies do not report sensitivity, specificity or area under the curve (AUC) measures for plasma Aβ levels, it is clear from these publications that determination of plasma Aβ levels is not useful as a diagnostic classifier.

Longitudinal results in the CN population and MCI and sporadic AD cases
-----------------------------------------------------------------------

Different measures of plasma Aβ have been associated with progression to dementia (Table [4](#T4){ref-type="table"}): high baseline Aβ~1-42~\[[@B30],[@B57]\], low baseline Aβ~1-42~/Aβ~1-40~\[[@B58],[@B59]\], low baseline Aβ~1-40~or Aβ~1-42~\[[@B60]\], high baseline Aβ~1-40~\[[@B29]\], high Aβ~1-40~or low Aβ~1-42~/Aβ~1-40~\[[@B61]\] and low Aβ~1-40~in older subjects \[[@B62]\]. Finally, other studies found no associations of plasma Aβ levels with progression to dementia \[[@B10],[@B13],[@B63]\]. A study including information on vascular risk factors in midlife and a long follow-up period after baseline plasma sampling found an increased risk of dementia in subjects with low Aβ~1-40~and Aβ~1-42~at baseline and there was an interaction between plasma Aβ levels and diastolic blood pressure that indicated a higher incidence of dementia in subjects with higher diastolic blood pressure and low plasma Aβ levels \[[@B60]\]. One study that compared Aβ plasma levels in CN and MCI subjects who remained cognitively stable or progressed to AD found no differences in these two different cohorts \[[@B13]\], but, as noted above, there were significant differences based on the CSF-defined groups.

###### 

Longitudinal studies in populations including sporadic Alzheimer\'s disease patients

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                   Subjects            Mean age at baseline (years)   Duration of follow-up (years)   Platform and antibodies   CV      Analyte associated with increased risk conversion to AD                   Magnitude
  --------------------------------------- ------------------- ------------------------------ ------------------------------- ------------------------- ------- ------------------------------------------------------------------------- ----------------
  Mayeux *et al.*1999 \[[@B30]\]          105 CNs\            73.4\                          3.5                             ELISA\                    \-      High baseline Aβ~1-42~                                                    HR = 3.6-4.0
                                          64 CNp              77.4                                                           6E10\                                                                                                       
                                                                                                                             R182\                                                                                                       
                                                                                                                             R165                                                                                                        

  Mayeux *et al.*2003 \[[@B27]\]          365 CNs\            75.5\                                                          ELISA\                    \-      High baseline Aβ~1-42~                                                    1.9-2.4
                                          86 CNp              79.3                                                           6E10\                                                                                                       
                                                                                                                             R182\                                                                                                       
                                                                                                                             R165                                                                                                        

  van Oijen *et al.*2006 \[[@B61]\]       1364 CNs\                                          8.5                             ELISA\                    \<15%   High baseline Aβ~1-40~\                                                   HR = 1.17\
                                          289 CNp\                                                                           6E10\                             Low baseline Aβ~1-42~/Aβ~1-40~                                            HR = 1.82
                                          103 CNp-OD                                                                         R226\                                                                                                       
                                                                                                                             R209                                                                                                        

  Graff-Radford *et al.*2007 \[[@B58]\]   510 CNs\            \-                             5                               ELISA\                    \-      Low baseline Aβ~1-42~/Aβ~1-40~                                            RR = 2.47-3.08
                                          53 CNp                                                                             BAN-50\                                                                                                     
                                                                                                                             BA27\                                                                                                       
                                                                                                                             BC05                                                                                                        

  Lopez *et al.*2008 \[[@B63]\]           117 CNs\            78.6\                          4.5                             ELISA                     \-      None                                                                      \-
                                          115 CNp\            79.9\                                                                                                                                                                      
                                          9 MCIs 33MCIp       80.5\                                                                                                                                                                      
                                                              79.6                                                                                                                                                                       

  Sundelöf *et al.*2008 \[[@B62]\]        608CNs\             \-                             11.2                            ELISA\                    \-      Low baseline Aβ~1-40~(only in the cohort older than 77 at baseline)       HR = 4.9
                                          74 CNp                                                                             BNT77\                                                                                                      
                                                                                                                             BA27\                                                                                                       
                                                                                                                             BC05                                                                                                        

  Schupf 2008 \[[@B57]\]                  104 MCIp 1021 CNs   80.7\                          4.5                             ELISA\                    \-      High baseline Aβ~1-42~Decrease of Aβ~1-42~Decrease of Aβ~1-42~/Aβ~1-40~   HR = 2.3-3.5\
                                                              76.3                                                           6E10\                                                                                                       HR = 2.6\
                                                                                                                             R182\                                                                                                       HR = 3.4
                                                                                                                             R165                                                                                                        

  Lambert *et al.*2009 \[[@B59]\]         985 CNs\            73.8\                          4                               xMAP INNO-BIA             \-      Low baseline Aβ~1-42~/Aβ~1-40~                                            HR = 2.0
                                          233 CNp             77.9                                                                                                                                                                       

  Blasko *et al.*2010 \[[@B78]\]          122 CNs\            \-                             5                               ELISA INNOTEST            \<17%   High baseline Aβ~1-42~                                                    OR = 1.7
                                          33 CNp                                                                                                                                                                                         

  Hansson *et al.*2010 \[[@B13]\]                                                                                            xMAP INNO-BIA             \<10%   No differences                                                            

  Toledo *et al.*2011 \[[@B10]\]          162 MCIs\           74.7\                          3.0                             xMAP INNO-BIA             \<10%   None                                                                      
                                          145 MCIp            74.6                                                                                                                                                                       

  Shah *et al.*2012 \[[@B60]\]            590 CNs\            \-                             15.8                            ELISA 2G3 21F12           \<20%   Low baseline Aβ~1-40~\                                                    HR = 2.1\
                                          53 MCIp\                                                                                                             Low baseline Aβ~1-42~                                                     HR = 1.6
                                          24 MCIp-VaD                                                                                                                                                                                    

  Hansson *et al.*2012 \[[@B29]\]         677 CNs 37 MCIp\    73.1\                          5                               xMAP INNO-BIA             \<10%   High baseline Aβ~1-40~                                                    OR = 2.2
                                          11 MCIp-VaD\        77.3\                                                                                                                                                                      
                                          5 MCIp-OD           78.9\                                                                                                                                                                      
                                                              78.8                                                                                                                                                                       
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AD, Alzheimer\'s disease; CNs, cognitively normal stable; CNp, cognitively normal progression; CNp-OD, cognitively normal progression to non-AD dementia; CSF, cerebrospinal fluid; HR, hazard ratio; MCIp-OD, mild cognitive impairment, progression to non-AD dementia; MCIp, mild cognitive impairment progressor (to AD); MCIp-VaD, mild cognitive impairment, progression to vascular dementia; MCIs, mild cognitive impairment stable; OD, other dementia; OR, odds ratio; RR, relative risk.

Other studies measuring plasma Aβ levels included correlations of these values with cognitive measures instead of using a diagnosis as outcome. One study included 481 subjects with a long follow-up and repeated measurements, and it used repeated brief telephone interviews for determining the study outcome, and the authors reported greater cognitive decline in subjects with a low Aβ~1-42~/Aβ~1-40~at baseline \[[@B64]\]. However, interassay CV was over 30% (repeated subject measurements were included in the same assay with CV \<10%). A larger study of 997 CN subjects followed for 9 years also found a faster cognitive decline in subjects with a lower Aβ~1-42~/Aβ~1-40~at baseline \[[@B65]\]. Cosentino *et al.*\[[@B66]\] followed 880 subjects for 4.5 years who were CN at baseline or had cognitive impairment that was not severe enough for a dementia diagnosis. In this study, subjects with higher baseline Aβ~1-40~and Aβ~1-42~and stable or decreasing Aβ~1-42~levels during follow-up had a faster rate of decline, whereas Aβ~1-42~/Aβ~1-40~showed no such association. On the other hand, in another study by Locascio *et al.*\[[@B67]\], the rate of cognitive decline in 122 AD patients was determined in subjects followed for 4.2 years, and these authors described a faster decline in subjects with lower plasma Aβ~1-40~and Aβ~1-42~at baseline. Two studies found an interaction between cognitive reserve and Aβ plasma levels, indicating that subjects with lower cognitive reserve showed a greater decline associated with Aβ levels \[[@B10],[@B65]\].

Longitudinal sampling of Aβ plasma measures
-------------------------------------------

A small number of studies have included repeated sampling of plasma Aβ levels \[[@B10],[@B27],[@B29],[@B57]\]. In the study by Mayeux *et al.*\[[@B27]\], a general increase was found for plasma Aβ~1-40~over time, and plasma Aβ~1-40~levels in CN stable subjects showed an increase over time, while incident and baseline AD subjects showed a decrease over time. A second study of the same group reported an increased incidence of dementia in CN subjects who showed a decrease in Aβ~1-42~and Aβ~1-42~/Aβ~1-40~during follow-up \[[@B57]\]. The study of Okereke *et al.*\[[@B64]\] found that a decrease in Aβ~1-42~/Aβ~1-40~in the repeated plasma measurement was associated with greater cognitive decline. Lastly, studies reported by Hansson *et al.*\[[@B29]\] and Toledo *et al.*\[[@B10]\] found that during follow-up of 324 subjects for 5 years in the former and 613 subjects for 2 to 3 years in the latter study, there was an increase of Aβ~1-40~and Aβ~1-42~, whereas Aβ~1-42~/Aβ~1-40~decreased.

Aβ plasma measures and cerebrovascular disease
----------------------------------------------

An association between plasma Aβ~1-40~and Aβ~1-42~levels in APOE ε4 carriers and in subjects known to have lacunar infarcts and white matter hyperintensities has been described in the Rotterdam study \[[@B28]\]. A second study that included subjects with cerebral amyloid angiopathy, MCI and AD also found an association between increased Aβ plasma and the presence of white matter hyperintensities and lacunar infarcts \[[@B68]\]. A third study specifically analyzed the association between microbleeds and plasma Aβ levels in subjects with AD and vascular dementia \[[@B69]\]. In this study, patients with nonlobar hemorrhages, located in the deep gray matter region and associated with hypertensive vasculopathy, showed higher Aβ~1-40~plasma levels compared to subjects with lobar hemorrhages, which are associated with cerebral amyloid angiopathy. In the ADNI cohort, we found no association between Aβ plasma levels and white matter hyperintensities, but subjects with infarcts on MRI had higher plasma Aβ~1-42~levels \[[@B10]\]. Finally, a longitudinal study by Lambert *et al.*\[[@B59]\] reported a higher incidence of vascular dementia in subjects with a low Aβ~1-42~/Aβ~1-40~.

Aβ plasma measures as biomarkers in clinical trials
---------------------------------------------------

Repeated sampling and measurement of plasma Aβ levels have been used to monitor the pharmacodynamic response of subjects in clinical trials of γ-secretase inhibitors (GSIs) and modulators (GSMs) as well as for passive immunotherapy. Studies in subjects treated with GSIs showed an initial dose-dependent decrease of total Aβ and Aβ~1-40~levels that was followed by a dose-independent increase of both analytes \[[@B70],[@B71]\]. A model based on a hypothetical inhibition of α-secretase by increases in C99 associated with GSI treatment has been proposed in order to explain these changes, but this remains to be proven \[[@B72]\]. Both studies by Siemers *et al.*\[[@B70],[@B71]\] did not report changes in CSF Aβ~1-40~and Aβ~1-42~levels, although the second sample was taken 4 hours after treatment and a longer timeframe might be needed to assess changes in the CSF levels of these Aβ species. Due to the worse cognitive outcome and secondary effects (severe gastrointestinal toxicity, immunomodulation and skin cancer) in patients treated with GSIs \[[@B73]\], research in this area has shifted towards GSMs that spare Notch signaling. These GSM have also shown a decrease of plasma Aβ \[[@B74]-[@B76]\] but the results regarding any Aβ-rebound are contradictory for GSMs \[[@B75],[@B76]\]. On the other hand, passive immunotherapy results from clinical trials suggest that there is a dose-dependent transient increase of plasma Aβ in response to the monoclonal anti-Aβ antibody infusion and this was reported to last several weeks \[[@B77]\]. Thus, more research is clearly needed to elucidate the effects of these disease-modifying therapies on plasma Aβ levels.

Conclusions
===========

Plasma Aβ is well known to originate in different organs and it also is known that Aβ binds to different proteins and cells in the blood, thereby possibly accounting for why plasma Aβ levels do not correlate with Aβ measured in CSF or CNS plaque burden measured by PET amyloid plaque imaging. Levels of plasma Aβ increase with aging and some clinical associations may change depending on the age of the selected sample. The selection of capture antibodies and analytical platforms can have an important impact on the measured Aβ levels; a wide range of mean Aβ~1-40~(214 \[[@B15]\] to 985 pg/ml \[[@B40]\]) and Aβ~1-42~(36 \[[@B15]\] to 140 pg/ml \[[@B19]\]) levels in AD patients has been reported in different studies and this also is the case for studies of CN subjects. Moreover, even in studies that use the same analytical platform and capture antibodies, there are important differences in the measured Aβ levels, which could be attributed to pre-analytical and analytical factors \[[@B10],[@B42]-[@B44],[@B48]\]. A recent study showed that automating multiple pipetting steps in a commercially available immunoassay that measures Aβ~1-42~and Aβ~1-40~provided better precision, thus leading to standardization of reagent dispensing in this test system \[[@B48]\]. Therefore, standardization efforts such as this and similar to the ones undertaken in the field of CSF Aβ measurements are needed \[[@B47]\]. Thus, this variability precludes the possibility of establishing diagnostic or prognostic cut-offs across different studies and populations until these assays are better standardized.

Using the profile of CSF tau and Aβ levels to define groups that have an underlying AD pathology reveals associations between subjects with and without AD-like CSF irrespective of a clinical diagnosis of CN, MCI or AD. Clinical diagnosis in the absence of a neuropathological validation or a CSF Aβ levels/PET plaque load validation may underestimate and confound the diagnostic/prognostic value of plasma Aβ measurements \[[@B2]\]. Cerebrovascular disease, which is a frequent finding in aged populations, is another important factor that can affect plasma Aβ levels and the prevalence of vascular risk factor and vascular disease varies considerably in the different samples according to the design of the study. While not useful as a diagnostic biomarker as shown by the cross-sectional studies, repeated Aβ plasma measurements in the same individual over time could become useful as a prognostic biomarker. Longitudinal studies favor the \'peripheral sink\' hypothesis with a decrease of plasma levels starting in the dementia stage in contrast to an increase of plasma Aβ during the pre-symptomatic stage so that disease stage-specific changes later in the course of AD may explain previously described conflicting results. Although the reported differences or changes in Aβ plasma levels might not be large enough to predict the longitudinal outcome, it is potentially possible that this biomarker can serve as a prognostic factor or as an endpoint during follow-up of AD patients. However, prospective studies of cohorts with subsequent neuropathology confirmation of their diagnosis or in concert with data on CSF tau and Aβ levels as well as other biomarker data are needed to establish how to best interpret data on plasma Aβ levels in CN, MCI and AD subjects with and without other comorbid conditions such as cerebrovascular disease.

Note
====

This article is part of a series on *Peripheral Biomarkers*, edited by Douglas Galasko. Other articles in this series can be found at <http://alzres.com/series/biomarkers>
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Aβ: amyloid beta; AD: Alzheimer\'s disease; ADNI: Alzheimer\'s Disease Neuroimaging Initiative; APOE: apolipoprotein E; APP: Aβ precursor protein; AV-45: florbetapir-F18; CN: cognitively normal; cnDS: cognitively normal Down syndrome; CNS: central nervous system; CSF: cerebrospinal fluid; CV: coefficient of variation; dDS: demented Down syndrome; DS: Down syndrome; ELISA: enzyme-linked immunosorbent assay; FAD: familial Alzheimer\'s disease; GSI: γ-secretase inhibitor; GSM: γ-secretase modulator; MCI: mild cognitive impairment; PET: positron emission tomography; PiB: Pittsburgh Compound-B-C11;.
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